Compare Organon & Co. Common Stock (OGN) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Wheaton Precious Metals Corp — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Wheaton Precious Metals Corp trades at $132.27 (market cap $61.55B). The key difference: Wheaton Precious Metals Corp is far larger — about 17× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays the higher dividend (0.58%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Wheaton Precious Metals Corp for 66 Days on average.
| OGN | WPM | |
|---|---|---|
Market Cap | $3.62B | $61.55B |
Volume | 2,892,999 | 932,802 |
Sector | Health | Basic Materials |
52-Week High | $13.81 | $165.72 |
52-Week Low | $5.70 | $94.37 |
Typical Hold Time | 0 Days | 66 Days |
Enterprise Value | $11.04B | $63.43B |
Dividend Yield | 0.58% | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Wheaton Precious Metals (WPM) trades at $129.58, down 6.18% over 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported record 2025 revenue of $2.31 billion and net income of $1.47 billion, with earnings beating estimates in recent quarters. Management targets 50% production growth by 2030 without new capital, supported by a strong deal pipeline.
WPM presents a growth opportunity with high profitability margins and analyst consensus favoring a buy rating, but faces risks from gold price volatility and execution of expansion plans. The stock's valuation multiples are elevated, requiring sustained earnings growth to justify current levels amid macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
